Ongoing research has significantly contributed to the design andevaluation of Hsp inhibitors as potential antileishmanial agents,with several inhibitors targeting leishmanial Hsps being tested., However, despite promising in vitro findings, challengesremain in translating these inhibitors into clinically effective therapiesfor leishmaniasis. The gene discussed is HSP90B2P; the disease is leishmaniasis.